The Pharmacy Times® Cervical Cancer Resource Center is a comprehensive resource for clinical news and expert insights for the type of cancer that occurs in the cells of the cervix.
March 21st 2024
Merck will also conduct clinical trials in both males and females to evaluate the efficacy of a single dose of their current human papillomavirus vaccine compared with the approved 3-dose regimen.
Risks and Liabilities in Pharmacy Practice
1.0 Credit / Law
View More
Background and Key Concepts in Biosimilars: Improving Awareness and Addressing Common Concerns
1.0 Credit / Law
View More
Clinical Conversations With the Cancer Care Team: Striving for Equitable Access to Oral Anticancer Medications
1.5 Credits / Law, Oncology
View More
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
Biomarkers Predict Response to Treatment in Cervical and Endometrial Cancers
February 24th 2021In a live virtual symposium presented at the 2020 ASHP Midyear Clinical Meeting and Exhibition, Allison Baxley, PharmD, BCOP, and Laura Alwan, PharmD, BCOP, engaged pharmacists in learning about the role of biomarkers in cervical and endometrial cancers.
Read More
FDA to Evaluate Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer
February 11th 2021A biologics license application has been submitted to the FDA for the accelerated approval of tisotumab vedotin for use in patients with recurrent or metastatic cervical cancer that has progressed on or following chemotherapy.
Read More
Biologics License Application for Bevacizumab Biosimilar BAT1706
January 29th 2021If approved, the biosimilar will be indicated for use in metastatic colorectal cancer, nonsquamous non–small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, and metastatic cervical cancer.
Read More
Researchers Conduct First-of-Its-Kind Review of National Data, HPV Vaccination Rates
January 26th 2021HPV is the most common sexually transmitted infection, and if a high-risk infection does not go away, it can lead to the development of a variety of cancers, including 91% of all cervical cancers, 70% of oropharyngeal cancers, and cancers of the vulva, vagina, and penis and anus.
Read More
Managing Therapies in Patients With Cervical and Endometrial Cancers
January 5th 2021Pharmacists play a key role in educating patients on risk factors for cervical and endometrial cancers and can assist with treatment decisions, and management of potential adverse effects in patients with these cancers.
Read More
Among patients with cervical cancer, there was no significant difference found between the risk of recurrence, local recurrence, or death among individuals who either completed or abandoned a radical uterine procedure following the intraoperative detection of a positive pelvic lymph node.
Read More
Natural Disasters May Affect Cervical Cancer Screening Rates
April 8th 2020Cervical cancer screening rates in Japan were significantly affected in the years following the devastating Great East Japan Earthquake of 2011, suggesting that disasters can affect cervical cancer screening for years.
Read More
Single Dose HPV Vaccine May Provide Similar Protection to Women as Multiple Doses
January 8th 2020The CDC has reported 34800 new cancer diagnoses linked to HPV annually, and the virus is predicted to account for more than 90% of all cervical and anal cancers, more than 60% of all penile cancers, and 70% of all oral cancers.
Read More
Study Shows Precancerous Cervical Lesions Have Declined
April 22nd 2019Precancerous cervical lesions, known as high-grade cervical lesions (CIN2+) can develop a few years after infection and have been used to monitor human papillomavirus (HPV) vaccine impact since cancers can take decades to develop.
Read More